So we have a number of drugs now in development, two which are very important stage for investors to understand. One is the drug called ALKS 9070. ALKS 9070 is our own long-acting injectable for the treatment of schizophrenia. In this case it’s a long-acting pro-drug of aripiprazole.
This will build up the foundation. It’s been build with RISPERDAL CONSTA and INVEGA SUSTENNA, two of our biggest commercial products already sold by Johnson & Johnson.
So we’ve come to understand the long-acting atypical antipsychotic market. It’s a big market. It’s a $2 billion franchise and growing double digits. Its still underserved in terms of the medical necessity for these products and ALKS 9070 fills a very clear niche in that market, which is a desire for long-acting form of one of the better tolerated antipsychotic.
And ABILIFY is that type of drug. It’s a $4 billion drug. We are developing the long-acting injectable in Phase 3. We should have results from that Phase 3 clinical trial next year and those data will be sufficient to file for FDA approval in United States.So 9070 is Phase 3 asset. It’s right in our power alley in schizophrenia long-acting medications and we are quite excited about it. Has a major effect in our models on evaluation if that drug is successful.Second drug I’ll mention then we can talk where we want to take is 5461. 5461 is a drug that you have to say is more risky at this moment, because its based on only one efficacy study so far.And that’s a drug for the treatment of depression, but particularly treatment-resistant depression for patients who have failed treatment with SSRI and conventional any depression medication.This is based on our deep understanding of opioid receptor biology, which is good in our chemistry capability and opioid receptor modulators, as well as our clinical experience with opioid receptor modulation through VIVITROL and other work.Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV